Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome Mads Laustsen to the Nanoform board. Mads is an exceptional entrepreneur with vast experience in the provision of GMP facilities and infrastructures. His outstanding experience will be incredibly valuable as we expand our manufacturing capacity and I thank the highly professional team at Coulter Partners for helping us once more to achieve such a quality appointment.”
Author: Alison James
On June 25, Coulter Partners hosted around 200 guests for a sparkling Summer Party in the beautiful gardens of the Walks, Gray’s Inn, London. International clients and colleagues joined the London team in the big marquee to celebrate a fabulous year!
We are delighted to announce the opening of new offices in Sydney and Singapore and three key appointments. Steven Johnson joins as Executive Director in Sydney, while Martin Grindrod is appointed Director in Singapore. In London, Rob Sansom joins as Director to consolidate the international Commercial Pharmaceutical team, working alongside Gert Andersen, Dr Christoph Themel, Mark Sharp and recently appointed Hugues Petit.
Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome David as a Director of the company and part of the senior leadership team and I thank Coulter Partners once more for their professional support in achieving this quality appointment. David’s deep knowledge of particle engineering platforms and experience with industrial scale production will be extremely valuable as we continue to expand our manufacturing capacity.”
“We are pleased that Ms. Beelen has joined Incysus at this key phase of development and thank the team at Coulter Partners for their outstanding professional support in achieving this appointment,” said William Ho, Chief Executive Officer of Incysus. “Melissa’s more than two decades of experience in drug development and clinical research will be invaluable as we take the next steps to develop commercially viable and effective allogeneic cellular immunotherapies for the treatment of cancer.”
In April Samantha Bower and Mat Rosso, two of Coulter Partners’ Pittsburgh team, ran far from home in their first London Marathon in aid of London based charity, Kith and Kids. Samantha came home in a truly athletic 2 hours and 57 minutes and was the 81st woman to cross the line!!! In his first ever marathon, former US professional figure skater, Mat completed the race in 4 hours and 40 minutes.
Samantha and Mat are running the LONDON MARATHON 2019 Two of Coulter Partners’ Pittsburgh team, Mat Rosso (Associate Director, Production) and Samantha Bower (Research Analyst), are this year running far from home in the 2019 London Marathon. Over the past 12 weeks, Mat Rosso and Samantha Bower have been hitting the pavement, sometimes begrudgingly, in Read More …
OxStem Co-Founder, Director and Waynflete Professor of Chemistry at the University of Oxford, Professor Steve Davies, said: “On behalf of the Board, Founders and management team, we warmly welcome Dr Stuart Collinson to OxStem and I thank the team at Coulter Partners for their outstanding professional support in achieving this appointment. Stuart is a highly experienced international business leader who brings significant fundraising, product development, partnering and commercialisation experience. We look forward to working with him to develop transformative medicines for patients suffering from severe degenerative diseases.”
Global Life Sciences search specialist, Coulter Partners is pleased to announce the opening of a new office in Paris and another 14 appointments worldwide, during an extremely successful year which has seen group sales grow by 31%. Business in the US has grown by 165% since last year and this region now accounts for 45% of group sales.
“We were delighted to work once more with Coulter Partners to identify Christa and bring her into Pivot Bio. Her experience is a great addition to our already strong leadership team,” said Karsten Temme, CEO and co-founder, Pivot Bio. “Christa will play a key role in Pivot’s growth as we expand the technology to new markets.”